- Home
- RPRX vs MEDP Comparison
RPRX vs MEDP Comparison
Compare RPRX & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- MEDP
- Stock Information
- Founded
- RPRX 1996
- MEDP 1992
- Country
- RPRX United States
- MEDP United States
- Employees
- RPRX 89
- MEDP N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- MEDP Biotechnology: Commercial Physical & Biological Resarch
- Sector
- RPRX Health Care
- MEDP Health Care
- Exchange
- RPRX Nasdaq
- MEDP Nasdaq
- Market Cap
- RPRX 13.6B
- MEDP 10.5B
- IPO Year
- RPRX 2020
- MEDP 2016
- Fundamental
- Price
- RPRX $30.93
- MEDP $345.89
- Analyst Decision
- RPRX Strong Buy
- MEDP Buy
- Analyst Count
- RPRX 6
- MEDP 10
- Target Price
- RPRX $41.67
- MEDP $389.00
- AVG Volume (30 Days)
- RPRX 3.4M
- MEDP 187.3K
- Earning Date
- RPRX 02-13-2025
- MEDP 02-10-2025
- Dividend Yield
- RPRX 2.74%
- MEDP N/A
- EPS Growth
- RPRX 518.56
- MEDP 33.84
- EPS
- RPRX 2.55
- MEDP 11.42
- Revenue
- RPRX $2,266,003,000.00
- MEDP $2,070,866,000.00
- Revenue This Year
- RPRX $14.54
- MEDP $13.95
- Revenue Next Year
- RPRX $10.94
- MEDP $5.49
- P/E Ratio
- RPRX $11.99
- MEDP $30.46
- Revenue Growth
- RPRX N/A
- MEDP 16.24
- 52 Week Low
- RPRX $24.05
- MEDP $286.76
- 52 Week High
- RPRX $31.66
- MEDP $459.77
- Technical
- Relative Strength Index (RSI)
- RPRX 75.82
- MEDP 51.50
- Support Level
- RPRX $29.73
- MEDP $338.00
- Resistance Level
- RPRX $31.09
- MEDP $350.00
- Average True Range (ATR)
- RPRX 0.73
- MEDP 9.45
- MACD
- RPRX 0.28
- MEDP 0.38
- Stochastic Oscillator
- RPRX 93.94
- MEDP 52.03
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About MEDP Medpace Holdings Inc.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.